Browse by category

Ascletis Pharma has completed enrolment in the US Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity. All 65 participants are obese or overweight with at least one weight-related comorbidity. The Phase IIa study of ASC30 once-monthly SQ depot treatment formulation is a 12-week, randomised, double-blind, placebo-controlled and multi-centre study co

Ascletis Pharma’s ASC47, a muscle-preserving weight loss drug candidate, in combination with semaglutide demonstrated up to 56.2% greater...

Ascletis Pharma has completed enrolment in its US 13-week Phase IIa study evaluating ASC30, a small molecule oral GLP-1 receptor (GLP-1R)...

The first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in Ascletis Pharma’s US...

Ascletis Pharma has announced pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in...

Ascletis Pharma has revealed positive interim results from the first two cohorts of its randomised, double-blind, placebo-controlled...

Ascletis Pharma has announced positive topline results from its US single ascending dose (SAD) study of ASC30 oral tablet in patients...

Ascletis Pharma has revealed in a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg,...

Ascletis Pharma has announced that results of its Phase I single ascending dose (SAD) study in Australia in subjects with elevated...